Department of Pediatric Nephrology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Department of Pediatric Nephrology, Kanuni Sultan Süleyman Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Pediatr Res. 2023 Feb;93(3):654-660. doi: 10.1038/s41390-022-02124-6. Epub 2022 Jun 9.
Our aim was to identify acute kidney injury (AKI) and subacute kidney injury using both KDIGO criteria and urinary biomarkers in children with mild/moderate COVID-19.
This cross-sectional study included 71 children who were hospitalized with a diagnosis of COVID-19 from 3 centers in Istanbul and 75 healthy children. We used a combination of functional (serum creatinine) and damage (NGAL, KIM-1, and IL-18) markers for the definition of AKI and subclinical AKI. Clinical and laboratory features were evaluated as predictors of AKI and subclinical AKI.
Patients had significantly higher levels of urinary biomarkers and urine albumin-creatinine ratio than healthy controls (p < 0.001). Twelve patients (16.9%) developed AKI based on KDIGO criteria, and 22 patients (31%) had subclinical AKI. AKI group had significantly higher values of neutrophil count on admission than both subclinical AKI and non-AKI groups (p < 0.05 for all). Neutrophil count was independently associated with the presence of AKI (p = 0.014).
This study reveals that even children with a mild or moderate disease course are at risk for AKI. Association between neutrophil count and AKI may point out the role of inflammation in the development of AKI.
The key message of our article is that not only children with severe disease but also children with mild or moderate disease have an increased risk for kidney injury due to COVID-19. Urinary biomarkers enable the diagnosis of a significant number of patients with subclinical AKI in patients without elevation in serum creatinine. Our findings reveal that patients with high neutrophil count may be more prone to develop AKI and should be followed up carefully. We conclude that even children with mild or moderate COVID-19 disease courses should be evaluated for AKI and subclinical AKI, which may improve patient outcomes.
本研究旨在使用 KDIGO 标准和尿液生物标志物来识别 COVID-19 轻症/中症患儿中的急性肾损伤(AKI)和亚急性肾损伤。
这项横断面研究纳入了来自伊斯坦布尔 3 家中心的 71 例 COVID-19 住院患儿和 75 例健康对照者。我们使用了功能(血清肌酐)和损伤(NGAL、KIM-1 和 IL-18)标志物的组合来定义 AKI 和亚临床 AKI。评估了临床和实验室特征作为 AKI 和亚临床 AKI 的预测因素。
与健康对照者相比,患儿的尿液生物标志物和尿白蛋白/肌酐比值显著升高(p<0.001)。根据 KDIGO 标准,12 例患者(16.9%)发生 AKI,22 例患者(31%)发生亚临床 AKI。AKI 组入院时的中性粒细胞计数明显高于亚临床 AKI 组和非 AKI 组(p<0.05)。中性粒细胞计数与 AKI 的存在独立相关(p=0.014)。
本研究表明,即使是轻症或中症患儿也有发生 AKI 的风险。中性粒细胞计数与 AKI 之间的关联可能提示炎症在 AKI 发展中的作用。
本文的关键信息是,不仅重症患儿,轻症或中症患儿也因 COVID-19 而发生肾损伤的风险增加。尿液生物标志物可在血清肌酐未升高的情况下诊断出大量亚临床 AKI 患者。我们的研究结果表明,中性粒细胞计数高的患者可能更容易发生 AKI,应密切随访。我们得出结论,即使是 COVID-19 轻症或中症患儿也应评估 AKI 和亚临床 AKI,这可能改善患者结局。